Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus VIVLODEX.
CHILDREN'S ADVIL-FLAVORED vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, resulting in antipyretic, analgesic, and anti-inflammatory effects.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription, up to 3200 mg/day under medical supervision.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
2-4 hours in children; prolonged in neonates (up to 30 hours) and hepatic impairment.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal excretion of conjugated metabolites (75-80% as glucuronide and sulfate conjugates, <10% as unchanged drug); biliary/fecal elimination accounts for <5%.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID